Get started
Author

Brendan Smyth

OpenAlex ID: A5137867904
Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease
2026 · Sunil V. Badve, Sunil V. Badve, et al. · JAMA · 6
PDF
Prevalence of Undertreated CKD among Hospital Inpatients: A Prospective Cross-Sectional Study.
2026 · Lucinda Wynter, Brendan Smyth, et al. · PubMed
Safety and Efficacy of Frexalimab in Participants With Relapsing Multiple Sclerosis: 2.5-Year Results From the Phase 2 Open-label Extension
2026 · Patrick Vermersch, Cristina Granziera, et al. · Multiple Sclerosis and Related Disorders
A National Survey of Kidney Supportive Care Services in Ireland
2026 · Sorcha O’Brien, Jacob Mackey, et al. · Kidney International Reports
PDF
Efficacy and Safety of Frexalimab in Participants With Relapsing Multiple Sclerosis: 3-Year Results From the Phase 2 Open-label Extension (P7-19.003)
2026 · Patrick Vermersch, Stephen Krieger, et al. · Neurology
Étude de phase 2 dans la SEP rémittente (SEP-R) évaluant l’efficacité et la sécurité d’emploi de Frexalimab (FREX) : données à 2,5 ans (120 semaines) de la période d’extension en ouvert
2026 · Patrick Vermersch, Cristina Granziera, et al. · Revue Neurologique
Works count: 6
Citation count: 6
H-index: 1
I10-index:
Year
Topic
Type